MedTrace Logo

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

NCT04594798 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Conditions

Interventions

DRUG

Polatuzumab vedotin

IV 1.8 mg/kg per cycle

DRUG

Rituximab

IV 375 mg/m2 per cycle

DRUG

Cyclophosphamide

IV 400 mg/m2 per cycle

DRUG

Doxorubicin

IV 25 mg/m2 per cycle

DRUG

Prednisone

PO 40 mg/m2 per cycle

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Patrick Reagan · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594798 on ClinicalTrials.gov